N/A
N=104
Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement
Ventral Incisional Hernia
Bottom Line
View on ClinicalTrials.gov: NCT01325792 ↗Enrolled (actual)
104
Serious AEs
2.9%
Results posted
Dec 2015
Primary outcome: Primary: Hernia Recurrence Rate — 17.3 % of subjects with recurrent hernia
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- GORE® BIO-A® Tissue Reinforcement (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- W.L.Gore & Associates
- Primary completion
- Dec 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hernia Recurrence Rate |
17.3 | — |
| SECONDARY Early and Long-term Complication Rates |
29.8 | — |
Summary
Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue Reinforcement when used to reinforce midline fascial closure in single-staged open complex ventral incisional hernia repair.
Eligibility Criteria
Inclusion Criteria
- Subjects will be informed about the study, and will have read; understood and signed the informed consent and authorization to use their PHI, as applicable
- Subjects willing and able to submit to postoperative follow-up evaluations including quality of life assessments up to 24 months after surgery
- Subjects of either gender that are at least the age of 18 years
- Subjects will have a Body-Mass Index (BMI) of 9 cm2 large when measured intraoperatively
- Subjects in which the required mobility for midline fascial closure without excessive tension to reapproximate the rectus abdominis muscle intraoperatively can be achieved
- Subjects in which one unit of GORE® BIO-A® Tissue Reinforcement will adequately reinforce the midline fascial closure with at least 4 cm of overlap laterally
Exclusion Criteria
- Subjects who, in the surgeon's opinion, would have a difficult time comprehending or complying with the requirements of the study
- Subjects with a BMI > 40
- Subjects with evidence of pre-existing systemic infections
- Subjects with cirrhosis or are currently being treated with dialysis
- Subjects with a wound-healing disorder
- Subjects with autoimmune disorder requiring > 10mg of a corticosteroid per day
- Subjects who are immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy
- Subjects with a hernia defect < 9 cm2 large when measured intraoperatively
- Subjects with a hernia defect requiring more than one unit of GORE® BIO-A® Tissue Reinforcement
- Subjects in which intraoperatively there is an inability to achieve retrorectus or intraperitoneal placement of the device
- Subjects in which a midline fascial closure without excessive tension cannot be achieved
- Subjects in which intraoperatively their surgical field/wound is characterized either a Type 1 or Type 4 in the Table 1 in Section 12
- Subjects in need of concomitant surgical procedures other than indicated in the protocol as acceptable
- Subject in which their complex ventral incisional hernia repair requires more than one operation to reduce hernia and close fascia, including serial excision procedures - requiring subsequent surgery to complete their hernia repair
- Subjects with a hernia repair requiring an emergent procedure, such as strangulated bowel
- Subjects in which intraoperatively untreated cancer was found
Data sourced from ClinicalTrials.gov (NCT01325792). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.